MIRA vs. MBRX, AKTX, ABVC, MTEM, ELAB, ERNA, GHSI, AVTX, AEZS, and GRTX
Should you be buying MIRA Pharmaceuticals stock or one of its competitors? The main competitors of MIRA Pharmaceuticals include Moleculin Biotech (MBRX), Akari Therapeutics (AKTX), ABVC BioPharma (ABVC), Molecular Templates (MTEM), Elevai Labs (ELAB), Eterna Therapeutics (ERNA), Guardion Health Sciences (GHSI), Avalo Therapeutics (AVTX), Aeterna Zentaris (AEZS), and Galera Therapeutics (GRTX). These companies are all part of the "pharmaceutical preparations" industry.
MIRA Pharmaceuticals (NASDAQ:MIRA) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, community ranking, risk, media sentiment and institutional ownership.
Moleculin Biotech received 227 more outperform votes than MIRA Pharmaceuticals when rated by MarketBeat users.
MIRA Pharmaceuticals' return on equity of 0.00% beat Moleculin Biotech's return on equity.
35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 6.7% of Moleculin Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Moleculin Biotech had 8 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 9 mentions for Moleculin Biotech and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 1.89 beat Moleculin Biotech's score of 1.02 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.
Moleculin Biotech has a consensus target price of $35.00, suggesting a potential upside of 635.29%. Given Moleculin Biotech's higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than MIRA Pharmaceuticals.
Summary
MIRA Pharmaceuticals and Moleculin Biotech tied by winning 5 of the 10 factors compared between the two stocks.
Get MIRA Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MIRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MIRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MIRA Pharmaceuticals Competitors List
Related Companies and Tools
